“Collectively, these findings identify sEVs released by senescent and aged cells as an important mechanism of intercellular communication and a key mediator of paracrine senescence.”

A new research paper was published in Volume 18 of Aging on October 8, 2026, titled “Small Extracellular Vesicles As Mediators of Paracrine Senescence in Cellular Models of Aging.” The paper is open-access.

The study found that small extracellular vesicles (sEVs) released by senescent cells can transmit signals that promote senescence in neighboring cells. Using human cellular models of aging, the researchers demonstrated that these membrane-enclosed particles could trigger cell-cycle arrest and DNA damage responses without activating the classical inflammatory pathways associated with senescence. The findings reveal another mechanism through which aging cells may influence their surroundings.

Full Story

Key Takeaways

• Deep-brain imaging in mammalian brains has been limited, because reaching greater depths typically requires more laser power, which can cause overheating and damage living brain tissue.
• By systematically redesigning every aspect of a microscopy platform, from how laser pulses are generated to how light is focused, researchers can now image activity of neurons 2 millimeters below the mouse brain’s surface while remaining within safe heating limits.
• The advance opens deep brain regions, such as the entire hippocampus and striatum, to optical imaging without removing the overlying cortex.

As light travels deeper into the brain, it scatters. Three-photon microscopy, the current state of the art, reduces the resulting background fluorescence and can, in principle, image much deeper than earlier techniques—but to do that, it uses average laser power limits that cause overheating and damage living tissue.

Full Story

Earlier this month (October 7, 2026), the biotech company Cerevance announced that its experimental Parkinson’s drug, solengepras, had succeeded in a large phase 3 clinical trial. Adding a once-daily solengepras pill to their usual medication regimen gave people with Parkinson’s more time each day with their symptoms under control, improved their ability to manage everyday activities, and eased their daytime sleepiness. “For some patients, this drug completely changed their life,” says Nathaniel Heintz, PhD, head of the Laboratory of Molecular Biology at Rockefeller. “It’s not just they move better; they feel better.” For Heintz—who identified the drug target behind solengepras nearly two decades ago—the new results are a success story because of how much they help patients. But they also offer some of the first real validation that drugs aimed at a single, precisely defined circuit in the brain can work to treat disease in people, an idea that Heintz has built his career around.

Full Story

The Huntington’s Disease Foundation has always championed funding research with extraordinary potential. When promising science offers a path toward disease-modifying treatments and, ultimately, a cure for Huntington’s disease, we are committed to making that research possible.

With the support of two new major donors, we are thrilled to announce that we have awarded not one, but two Transformative Research Awards for 2026 – one led by Rachel Harding, PhD, of the Structural Genomics Consortium and University of Toronto, and the other led by Ai Yamamoto, PhD,of Columbia University. They each will receive funding of $1 million over the next two years to advance their work toward developing treatments for Huntington’s disease.

Full Story

Inspired by bacterial biology, the Gladstone-developed “Detectron” opens up new possibilities for disease research and potentially treatments. Inside every cell, RNA acts as a vital messenger. Its levels rise when genes are active, while specific fragments can serve as clear warning signs of a viral infection. Reading these cellular messages gives scientists a direct window into human health, but finding and measuring specific RNA strands inside a cell is often a cumbersome, multi-step process.

To simplify it, researchers at Gladstone Institutes have built a customizable biosensor called the “Detectron.” With mechanics borrowed from retrons, an ancient defense mechanism found in bacteria, the Detectron functions like a smart tripwire: the moment it senses a target RNA strand, it responds by churning out distinct, easy-to-read DNA “barcodes.”

Full Story

A new study led by Boston University researchers estimates that nearly 75% of all NFL players who died between 2008 and 2023 had chronic traumatic encephalopathy (CTE) neuropathology. CTE is a neurodegenerative disease that has been diagnosed in individuals with substantial exposure to repetitive head impacts. It can only be definitively diagnosed after death.

“Providing a precise estimate for the prevalence of CTE among deceased NFL players helps define the scale of the problem and informs priorities for the potential current and future medical needs of this community,” said Julia Gallini, lead author and a PhD candidate at Boston University School of Public Health. “With CTE consistently found in less than 1% of donors to community brain banks, an estimated 75% prevalence among NFL players who died over a 16-year period is concerning, and suggests we need to increase efforts to support families, diagnose CTE during life, and treat CTE-related symptoms.”

Full Story

Join Illumina at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo in Seattle, November 10-14. As a trusted partner in precision oncology research, we invite you to visit Illumina booth 727 to discover how we’re helping laboratories advance precision genomics today while preparing for the future of genomic research. Our booth will highlight the MiSeq i100 system, SPT fireflyGO, Illumina BioInsight platform, IVD corner featuring FDA-approved TruSight Oncology Comprehensive and Pillar oncoReveal®, and Medical Affairs & Market Access education and consultation opportunities. Illumina Corporate Workshops and Innovation Spotlight talk will highlight solutions that laboratories can depend on across the continuum of precision oncology research. From accessible sequencing and AI-assisted informatics to comprehensive genomic and epigenomic profiling, Illumina is delivering proven technologies and expertise that help laboratories expand capabilities, generate reliable insights, and evolve with changing clinical research needs. Learn more about our talk topics and presentation details below.

Full Story

Dengue virus is especially pernicious compared with many other viruses, as secondary infections can actually be worse than the first one. Now, a new phase 1 trial involving controlled infections in volunteers provides a treasure trove of details about how preexisting immunity and anti-dengue antibodies affect the nature of secondary infections with dengue. The findings are among the first to glean insights using a large controlled human challenge, and could inform future therapeutics and the design of more broadly protective vaccines. Secondary infections with dengue are often the most severe ones, as preexisting antibodies can boost viral counts and raise the risk of severe symptoms. This has frustrated the development of badly needed vaccines for dengue. Furthermore, it’s been challenging to understand how pre-infection affects dengue outcomes, as animal models have many limitations and patients usually don’t present until after viral counts have peaked.

Full Story

• Australian researchers map, in unprecedented detail, the immune cells through which genetic differences between people influence disease.
• The researchers analyzed the gene sequence and activity of more than 5 million individual immune cells from nearly 2,000 people, the largest dataset of its kind in the world.
• The findings open a path to precision medicine for diseases ranging from autoimmune conditions like multiple sclerosis to neurological conditions such as Alzheimer’s and cancers including breast and prostate.

In three landmark studies published in Nature October 28, 2026, Australian researchers have made major advances in our understanding of how genetic differences between people influence disease. The team from the Garvan Institute of Medical Research, in collaboration with the Murdoch Children’s Research Institute, UNSW and other partners, linked genetic risk regions for 16 diseases to possible causes in specific immune cells, identifying nearly 1,500 genes that may contribute to a range of diseases. These discoveries are set to accelerate drug development and precision medicine across many diseases, ranging from cancers to immune and neurological conditions. The work is the first major output of the TenK10K project, which seeks to map genetic variation and gene activity in immune cells from 10,000 people.

Full Story

Much remains unknown about the origin of viruses and how they evolve — but hunting for answers has been the focus of Portland State University biology professor Ken Stedman’s eXtreme Virus Lab for the past 25 years. 

DNA viruses, like monkeypox, were long thought to evolve completely separately from RNA viruses, like influenze. But in 2012, Stedman’s lab was the first to publish findings on a newly discovered group called cruciviruses, which appear to have evolved through an unprecedented recombination between RNA and DNA viruses. Since then, hundreds of cruciviruses have been identified from environmental samples ranging from Antarctic lake water to the soil on PSU’s own campus. The eXtreme Virus Lab is one of the few, if not the only, in the world dedicated to studying cruciviruses. 

Full Story